Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. decreased its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 82.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 37,000 shares of the biotechnology company’s stock after selling 176,630 shares during the period. D.A. Davidson & CO.’s holdings in Heron Therapeutics were worth $57,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HRTX. JPMorgan Chase & Co. raised its position in Heron Therapeutics by 295.8% in the third quarter. JPMorgan Chase & Co. now owns 206,711 shares of the biotechnology company’s stock worth $411,000 after acquiring an additional 154,487 shares in the last quarter. Principal Financial Group Inc. grew its stake in shares of Heron Therapeutics by 456.5% in the 3rd quarter. Principal Financial Group Inc. now owns 102,651 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 84,205 shares during the last quarter. Verition Fund Management LLC raised its holdings in shares of Heron Therapeutics by 340.0% in the 3rd quarter. Verition Fund Management LLC now owns 108,115 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 83,542 shares in the last quarter. Congress Park Capital LLC lifted its stake in Heron Therapeutics by 24.1% during the fourth quarter. Congress Park Capital LLC now owns 2,455,495 shares of the biotechnology company’s stock valued at $3,757,000 after purchasing an additional 477,417 shares during the last quarter. Finally, Barclays PLC lifted its stake in Heron Therapeutics by 29.8% during the third quarter. Barclays PLC now owns 218,455 shares of the biotechnology company’s stock valued at $434,000 after purchasing an additional 50,109 shares during the last quarter. 80.01% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on HRTX shares. StockNews.com cut Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and issued a $4.00 target price on shares of Heron Therapeutics in a report on Wednesday, December 4th.

Heron Therapeutics Price Performance

Shares of HRTX opened at $2.05 on Friday. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The company has a 50-day moving average of $1.67 and a two-hundred day moving average of $1.71. The stock has a market cap of $311.79 million, a price-to-earnings ratio of -11.39 and a beta of 1.60.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The firm had revenue of $40.78 million during the quarter, compared to analyst estimates of $37.37 million. Analysts anticipate that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.